Aardvark Therapeutics, Inc. Common Stock (AARD) — QMA analysis
Sector: Healthcare · Market cap: $283M · Price: $1.39 · Data as of 2026-10-23
Aardvark Therapeutics, Inc. Common Stock has a below-average composite score of 44/100, higher score than 50% of 22,734 tracked stocks. The highest-scoring layer is Analysts / transcripts; the lowest is Insider activity.
What 9 data layers say about AARD
The composite fuses insiders, congressional trades, institutional 13F positions, fundamentals, momentum, seasonality and more into a single number.
| Layer | Score |
|---|---|
| Fundamental value (FVS) | 43/100 |
| Technical trend (TSS) | 54/100 |
| Relative strength (RS) | 12/100 |
| Momentum (USS) | 29/100 |
| Insider activity (IAS) | 11/100 |
| Off-exchange trading (FINRA) / large flows (WHS) | 24/100 |
| News sentiment (NSS) | 58/100 |
| Analysts / transcripts (ATS) | 76/100 |
| Catalysts (XS) | 76/100 |
What does the QMA model currently show for Aardvark Therapeutics, Inc. Common Stock?
The composite score is a research starting point, not an instruction. What matters is layer confluence — whether the layers point in the same direction.
For AARD the layers diverge — some score high (Analysts / transcripts), others low (Insider activity). The divergence is itself information: the model does not give a clear-cut picture. The score is an input into your own research, not a recommendation.
AARD insider & smart money activity
Over the recent period we record 0 reported insider purchases and 0 sales for AARD: no reported insider trades in the period. A description of the data layer, not an instruction.
How AARD compares
Similar stocks from the same sector:
Frequently asked questions
What is the composite score for AARD stock?
44/100 (D) — Data as of 2026-10-23.
Are insiders buying AARD stock?
Over the recent period, reported: purchases 0, sales 0. Insider activity: no reported insider trades in the period — a description of reported data, not a trade instruction.
Where can I see live AARD data?
Live AARD data and the full screener are part of full access. Registration is free with no card — trial full access, then the free plan with a delayed data sample.
Data from SEC and public markets. QMA is an analytical tool, not a registered investment advisor. No content on this page is investment advice or an instruction to buy or sell. Past performance does not guarantee future results.
⚠️ Important Notice: QMA is an analytical and educational tool, not investment advice. Scores, detections and ratings are descriptive, not buy/sell instructions. QMA is not a registered investment advisor (SEC / FINRA / MiFID II / ČNB). Consult a licensed financial advisor before any investment. Past performance does not guarantee future results; all investments carry the risk of capital loss.
Operator: Jaroslav Vojtášek · IČO: 48783447 · Place of business: U Jízdárny 577, 747 64 Velká Polom, Czech Republic · Register: Sole trader registered in the Czech Trade Licensing Register · E-mail: [email protected]